Ocugen, Inc. (OCGN) stock
OCGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.83−0.05 (-5.24%)
Close on Nov 13, 2026Market cap $280.72MP/E –Yield –
Ocugen total assets
Total assets on the balance sheet at the end of each period.
Ocugen's total assets was $108.06M at Sep 30, 2026. For fiscal 2025 it was $43.52M, down 47.2% from the year before. Over ten years it grew 1.7% a year on average. The highest annual figure on record is $108.63M in fiscal 2022.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $43.52M | -47.2% |
| FY2024 | Dec 31, 2024 | $82.44M | +27.7% |
| FY2023 | Dec 31, 2023 | $64.55M | -40.6% |
| FY2022 | Dec 31, 2022 | $108.63M | +2.7% |
| FY2021 | Dec 31, 2021 | $105.76M | +286.3% |
| FY2020 | Dec 31, 2020 | $27.38M | +62.9% |
| FY2019 | Dec 31, 2019 | $16.81M | +584.8% |
| FY2018 | Dec 31, 2018 | $2.45M | -77.8% |
| FY2017 | Dec 31, 2017 | $11.04M | -69.4% |
| FY2016 | Dec 31, 2016 | $36.08M | -1.9% |
| FY2015 | Dec 31, 2015 | $36.79M | -43.8% |
| FY2014 | Dec 31, 2014 | $65.50M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $108.06M | +87.6% |
| Q2 FY2026 | Jun 30, 2026 | $124.21M | +131.8% |
| Q1 FY2026 | Mar 31, 2026 | $56.91M | -11.7% |
| Q4 FY2025 | Dec 31, 2025 | $43.52M | -47.2% |
| Q3 FY2025 | Sep 30, 2025 | $57.60M | -7.0% |
| Q2 FY2025 | Jun 30, 2025 | $53.59M | +32.2% |
| Q1 FY2025 | Mar 31, 2025 | $64.46M | +24.5% |
| Q4 FY2024 | Dec 31, 2024 | $82.44M | +27.7% |
| Q3 FY2024 | Sep 30, 2024 | $61.94M | -17.1% |
| Q2 FY2024 | Jun 30, 2024 | $40.54M | -54.4% |
| Q1 FY2024 | Mar 31, 2024 | $51.79M | -46.2% |
| Q4 FY2023 | Dec 31, 2023 | $64.55M | -40.6% |
| Q3 FY2023 | Sep 30, 2023 | $74.69M | -35.7% |
| Q2 FY2023 | Jun 30, 2023 | $88.98M | -31.6% |
| Q1 FY2023 | Mar 31, 2023 | $96.30M | -32.1% |
| Q4 FY2022 | Dec 31, 2022 | $108.63M | +2.7% |
| Q3 FY2022 | Sep 30, 2022 | $116.24M | -0.1% |
| Q2 FY2022 | Jun 30, 2022 | $130.09M | +4.7% |
| Q1 FY2022 | Mar 31, 2022 | $141.73M | +163.2% |
| Q4 FY2021 | Dec 31, 2021 | $105.76M | +286.3% |
| Q3 FY2021 | Sep 30, 2021 | $116.31M | +466.3% |
| Q2 FY2021 | Jun 30, 2021 | $124.25M | +423.0% |
| Q1 FY2021 | Mar 31, 2021 | $53.85M | +337.3% |
| Q4 FY2020 | Dec 31, 2020 | $27.38M | +62.9% |
| Q3 FY2020 | Sep 30, 2020 | $20.54M | -13.0% |
| Q2 FY2020 | Jun 30, 2020 | $23.76M | +642.5% |
| Q1 FY2020 | Mar 31, 2020 | $12.31M | -17.0% |
| Q4 FY2019 | Dec 31, 2019 | $16.81M | +584.8% |
| Q3 FY2019 | Sep 30, 2019 | $23.62M | +117.1% |
| Q2 FY2019 | Jun 30, 2019 | $3.20M | -78.9% |
| Q1 FY2019 | Mar 31, 2019 | $14.84M | -30.4% |
| Q4 FY2018 | Dec 31, 2018 | $2.45M | -77.8% |
| Q3 FY2018 | Sep 30, 2018 | $10.88M | -31.3% |
| Q2 FY2018 | Jun 30, 2018 | $15.15M | -31.5% |
| Q1 FY2018 | Mar 31, 2018 | $21.33M | -24.7% |
| Q4 FY2017 | Dec 31, 2017 | $11.04M | -69.4% |
| Q3 FY2017 | Sep 30, 2017 | $15.83M | – |
| Q2 FY2017 | Jun 30, 2017 | $22.13M | – |
| Q1 FY2017 | Mar 31, 2017 | $28.31M | – |
| Q4 FY2016 | Dec 31, 2016 | $36.08M | – |
See a number that looks wrong?